Results 91 to 100 of about 12,467 (245)

Newborn screening for cystic fibrosis [PDF]

, 2016
Since the late 1970s when the potential of the immunoreactive trypsinogen assay for early identification of infants with cystic fibrosis was first recognised, the performance of newborn blood spot screening (NBS) has been continually assessed and its use
Castellani, C, Massie, J, Sontag, M, Southern, KW   +3 more
core   +1 more source

Pediatric Lung Waitlist Score (PLWS): A Score to Predict Waitlist Time for Pediatric Lung Transplant Candidates

Clinical Transplantation, Volume 40, Issue 1, January 2026.
ABSTRACT Background: In pediatric lung transplantation, the ability to estimate the projected waiting time could be particularly helpful for candidates and physicians. A score to predict waiting time has yet to be developed in this field. The purpose of this study was to create a score that predicts waitlist time for pediatric patients who are listed ...
Jose Ramirez, Spoorthi Kamepalli, Abbas Rana   +2 more
wiley   +1 more source

Governments need better guidance to maximise value for money: the case of Australia’s Pharmaceutical Benefits Advisory Committee [PDF]

, 2016
Published online: 27 January 2016In Australia, the Pharmaceutical Benefits Advisory Committee (PBAC) makes recommendations to the Minister for Health on which pharmaceuticals should be subsidised.
Carter, D.A., Haji Ali Afzali, H., Vogan, A.   +2 more
core   +1 more source

The use of Multiple Breath Washout for Assessing Cystic Fibrosis in Infants [PDF]

, 2016
INTRODUCTION: Lung Clearance Index, measured using the multiple breath washout (MBW) technique, may be a useful test in infants with Cystic Fibrosis (CF).
Aurora, P, Davies, G
core   +1 more source

CFTR Modulator Therapy Enhances Peripheral Blood Monocyte Contributions to Immune Responses in People With Cystic Fibrosis

Frontiers in Pharmacology, 2020
BackgroundCFTR modulators decrease some etiologies of CF airway inflammation; however, data indicate that non-resolving airway infection and inflammation persist in individuals with CF and chronic bacterial infections.
Katherine B. Hisert, Katherine B. Hisert, Timothy P. Birkland, Kelly Q. Schoenfelt, Matthew E. Long, Brenda Grogan, Suzanne Carter, W. Conrad Liles, Edward F. McKone, Lev Becker, Anne M. Manicone, Sina A. Gharib   +11 more
doaj   +1 more source

P323 Does elexacaftor/tezacaftor/ivacaftor triple therapy significantly raise blood lipids? A longitudinal cohort study [PDF]

, 2023
R J Docherty, J. Still, Owen Dempsey
openalex   +1 more source

From Pathophysiology to Treatment: Contemporary Approaches to CFRD in the Pediatric and Adolescent Population

Pediatric Diabetes, Volume 2026, Issue 1, 2026.
Cystic fibrosis‐related diabetes (CFRD) is the most prevalent nonrespiratory complication of cystic fibrosis (CF), with its prominence growing as survival rates improve due to advances in CFTR modulator therapies. Its prevalence increases with age, affecting nearly 50% of patients with CF (PwCF) over 30 years old.
Dogus Vuralli, Andrea Scaramuzza
wiley   +1 more source

Ivacaftor ameliorates mucus burden, bacterial load, and inflammation in acute but not chronic P. aeruginosa infection in hG551D rats

Respiratory Research
Background Newly approved highly effective modulation therapies (HEMT) have been life-changing for people with CF. Although these drugs have resulted in significant improvements in lung function and exacerbation rate, bacterial populations in the lung ...
Johnathan D. Keith, Mikayla Murphree-Terry, Gretchen Bollar, Ashley M. Oden, Ian H. Doty, Susan E. Birket   +5 more
doaj   +1 more source

Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation [PDF]

European Respiratory Review, 2013
Cystic fibrosis (CF) is an autosomal recessive lethal disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that encodes for CFTR, an epithelial cell-surface expressed protein responsible for the transport of ...
Isabelle Sermet-Gaudelus
doaj  

The importance of data issues when comparing cystic fibrosis registry outcomes between countries : are annual review FEV1 in the UK only collected when subjects are well? [PDF]

, 2018
Rationale, aims and objective Cross‐country comparisons of cystic fibrosis (CF) outcomes can potentially identify variation in care but are dependent on data quality.
Corey, Elborn, Etherington, Fuchs, Goss, Goss, Hoo, Johnson, Knapp, Konstan, MacKenzie, Martin, Mauch, Mohammed, Morgan, Ramsey, Schechter, Stallings, Stephenson, Stephenson, Sykes, Viviani, Zemel   +22 more
core   +1 more source